Capitalizing on the surging momentum within Hematology and Oncology, new leadership positions are being instated.
Two renowned experts in pediatric hematology/oncology, Dr. Jamie Flerlage and Dr. Jeffrey Andolina, have been appointed as the new leaders in their respective fields at Golisano Children’s Hospital.
Dr. Jamie Flerlage, a specialist in childhood cancers and blood disorders, has been appointed as the division chief and academic director of the Division of Pediatric Hematology/Oncology. Dr. Flerlage is nationally and internationally recognized for her expertise in pediatric Hodgkin's lymphoma. She leads national and international groups focused on research and clinical trials for Hodgkin's lymphoma, with a research focus on novel therapies for patients with the disease and on identifying genome sequences to pinpoint genetic variants related to hematopoietic malignancy. In her new roles, Dr. Flerlage will work to expand external and collaborative clinical research opportunities in Rochester and beyond.
Dr. Fleragon's appointment has been met with enthusiasm by Dr. Jonathan W. Friedberg, MD, MMSc, director of Wilmot Cancer Institute. He expressed that Dr. Flerlage will be a tremendous asset for their clinical research efforts, particularly in childhood cancers. Dr. Flerlage will also serve as an assistant director of Clinical Research within Wilmot Cancer Institute's Clinical Trials Office (CTO).
Dr. Jeffrey Andolina, a renowned clinician and leader with expertise in the treatment and care of children with leukemia and lymphoma, as well as other cancers and blood diseases, has been appointed as the clinical director of Pediatric Hematology and Oncology and associate chair for Pediatric Program Development for Golisano Children's Hospital. In his leadership role, Dr. Andolina will direct inpatient and outpatient clinical services for the division, lead clinical program development, and promote a unified approach to the medical care of pediatric hematology/oncology patients.
Dr. Jill Halterman, MD, MPH, interim chair of the Department of Pediatrics, expressed optimism about the leadership of Drs. Andolina and Flerlage, stating that they will contribute to the continuation of progress in the clinical mission and the development of advanced treatments to serve children in New York State and beyond. Together, they provide leadership to the division, emphasizing both clinical care and research to improve outcomes for children facing cancer and blood disorders at Golisano Children’s Hospital.
Dr. Flerlage is scheduled to start on October 1. Both Dr. Andolina and Dr. Flerlage will work towards advancing GCH's growing reputation in the field of pediatric cancer. The Division of Pediatric Hematology/Oncology at Golisano Children's Hospital was nationally ranked in 2023 by U.S. News & World Report.
- Dr. Flerlage's expertise in pediatric Hodgkin's lymphoma, coupled with her leadership in national and international research groups focused on clinical trials, will contribute significantly to the health-and-wellness of children battling cancer by paving the way for novel therapies and identifying genetic variants related to hematopoietic malignancy.
- Dr. Jeffrey Andolina's vast knowledge in the treatment and care of various pediatric cancers and blood diseases, as well as his business acumen demonstrated through his leadership roles, will be instrumental in driving the finance and expansion of the division's clinical services at Golisano Children's Hospital.
- The appointment of both Dr. Jamie Flerlage and Dr. Jeffrey Andolina as leaders in their respective fields at Golisano Children’s Hospital signals a promising future for science, as these experts will collaborate to advance clinical trials and provide groundbreaking medical-conditions care, ultimately improving the lives of pediatric patients with cancer and blood disorders across New York State and beyond.
